DBV Technologies (DBVT) Income from Continuing Operations (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Income from Continuing Operations of 50400000.0 for Q2 2026, down 20.29% year-on-year from 63226347.31 in Q2 2025, and down 5.88% on a QoQ basis from 47600000.0 in Q1 2026.
DBV Technologies (DBVT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Income from Continuing Operations for 7 consecutive years, with 50400000.0 the latest figure, recorded in Q2 2026.
- Quarterly Income from Continuing Operations fell 20.29% year-over-year to 50400000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 175993000.0 (down 43.72% YoY) and the FY2025 annual result came in at 146947000.0, down 28.99% from the prior year.
- Income from Continuing Operations fell to 50400000.0 in Q2 2026 per DBVT's latest filing, from 47600000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for DBVT reached as high as 11186000.0 in Q4 2023 and fell as low as 50400000.0 in Q2 2026.
- A 5-year average of 29328333.33 and a median of 27222500.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 187.02% — and 2023, when it jumped 71.49%.
- Year by year, Income from Continuing Operations stood at 39241000.0 in 2022, then soared by 71.49% to 11186000.0 in 2023, then slumped by 105.75% to 23015000.0 in 2024, then slumped by 94.78% to 44829000.0 in 2025, then slipped by 12.43% to 50400000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 50400000.0, 47600000.0, and 44829000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | -50.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.40 Mn |
| Mar 31, 2026 | -47.60 Mn |
| Dec 31, 2025 | -44.83 Mn |
| Sep 30, 2025 | -33.16 Mn |
| Jun 30, 2025 | -41.90 Mn |
| Mar 31, 2025 | -27.10 Mn |
| Dec 31, 2024 | -23.02 Mn |
| Sep 30, 2024 | -30.44 Mn |
| Jun 30, 2024 | -33.12 Mn |
| Mar 31, 2024 | -27.35 Mn |
| Dec 31, 2023 | -11.19 Mn |
| Sep 30, 2023 | -16.74 Mn |
| Jun 30, 2023 | -24.24 Mn |
| Mar 31, 2023 | -20.56 Mn |
| Dec 31, 2022 | -39.24 Mn |
| Sep 30, 2022 | -17.29 Mn |
| Jun 30, 2022 | -23.04 Mn |
| Mar 31, 2022 | -16.71 Mn |
| Dec 31, 2021 | -13.67 Mn |
| Sep 30, 2021 | -24.03 Mn |